NCT07468708RecruitingEarly phase 1
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
Evaluation of Dosimetry, Safety, Biodistribution and Preliminary Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled prostate cancer-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 9 Mar 2026
- Start date
- 9 Mar 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
- Diseases
- Prostate cancer
- NCT number
- NCT07468708
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 10
- From 9 Mar 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe impairment of liver, kidney, or cardiac function;
- Severe obesity or other conditions that prevent or make PET/CT scanning impossible;
- Hypersensitivity to any active or inactive components of the study drug;
Other
- Other subjects deemed unsuitable for enrollment by the investigators.
Who the study is looking for
- Voluntarily participate the clinical study; sign the informed consent form;
- Aged 18 years or older;
- Cohort A: Healthy subjects;
- Cohort B: Patients with prostate cancer confirmed by histopathological or cytological diagnosis;
Age in the registry: 18 years to - · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Jinan University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.